Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 6/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580070 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL2944337 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL5966050 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL5580017 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL3199941 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL20078981 | 1.00 | TBXAS1 (0.47) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL5966061 | 0.98 | TBXAS1 (0.44) | TBXAS1TBXA2RCES2CES1L3MBTL1 | |
| SCHEMBL28774336 | 0.93 | TBXAS1 (0.42) | TBXAS1TBXA2RCES2CES1TDP1 | |
| SCHEMBL9735799 | 0.91 | ALDH1A1 (0.49) | TBXA2RFAAHTDP1MEN1KMT2A | |
| SCHEMBL10428746 | 0.91 | ALDH1A1 (0.49) | TBXA2RFAAHTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273116-A1 | SILVER HALIDE PHOTOSENSITIVE MATERIAL | FUJIFILM CORPORATION (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20070191274-A1 | Active hedgehog protein conjugate | ONTOGENY, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070065869-A1 | Methods for producing ligand arrays | HARGREAVES JOHN S | 2007-03-22 | — | — | US | disclosed |
| US-7153836-B2 | Active hedgehog protein conjugate | CURIS, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1594883-A2 | COVALENT MODIFICATION OF RNA FOR IN VITRO AND IN VIVO DELIVERY | Mirus Corporation (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-0953576-B1 | Active hedgehog protein conjugate, process for its production and use | CURIS INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1557427-A2 | Hedgehog protein conjugate | Curis, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148510-A1 | Active hedgehog protein conjugate | CURIS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6818623-B2 | COMPRISES MORPHOGENIC TRANSMEMBRANE POLYPEPTIDE WITH INCREASED ACTIVITY FOR TREATING BONE, NEURODEGENERATIVE AND MUSCLE DISORDERS | CURIS, INC. | 2004-11-16 | — | — | US | disclosed |
| WO-2004076630-A2 | COVALENT MODIFICATION OF RNA FOR IN VITRO AND IN VIVO DELIVERY | MIRUS CORPORATION (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040167090-A1 | Covalent modification of RNA for in vitro and in vivo delivery | Arrowhead Madison Inc. | 2004-08-26 | — | — | US | disclosed |
| US-20030139574-A1 | Active hedgehog protein conjugate | ROCHE DIAGNOSTICS GMBH (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6468978-B1 | CONJUGATE COMPRISING 1 TO 4 MOIETIES COVALENTLY BOUND TO POLYPEPTIDE COMPRISING HEDGEHOG N-TERMINAL DOMAIN, EACH BEING POLYPEPTIDE CONTAINING 10 TO 30 HYDROPHOBIC AMINO ACIDS OR POSITIVELY CHARGED AMINO ACIDS FORMING TRANSMEMBRANE HELICES | CURIS, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-0953576-A1 | Active hedgehog protein conjugate, process for its production and use | BOEHRINGER MANNHEIM GMBH (DE) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167090-A1 | Covalent modification of RNA for in vitro and in vivo delivery | NSUN2, NSUN3, RNASE1 | TBXAS1 4219/4885TBXA2R 4736/4885CES2 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.